Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News AbbVie’s Imbruvica shows benefits in treatment of Waldenstrom’s macroglobulinemia

AbbVie’s Imbruvica shows benefits in treatment of Waldenstrom’s macroglobulinemia

8th December 2017

AbbVie has announced the findings of a new clinical trial that demonstrate the benefits that Imbruvica can offer in the treatment of a rare form of non-Hodgkin's lymphoma.

Positive data has been published from the phase III iNNOVATE trial, which evaluated Imbruvica in combination with rituximab in patients with treatment-naive and previously-treated Waldenstrom's macroglobulinemia (WM).

The regimen demonstrated improvements in progression-free survival rates compared to rituximab alone, leading an independent data monitoring committee to recommend that the study be unblinded.

Imbruvica is a first-in-class Bruton's tyrosine kinase inhibitor and is the only current therapy option for this rare form of cancer. The drug was jointly developed and commercialised by Pharmacyclics, an AbbVie company, and Janssen Biotech.

Dr Thorsten Graef, head of clinical development at Pharmacyclics, said: "We continue to be committed to exploring the full potential of Imbruvica, and are pleased to add the results of iNNOVATE to our growing scientific understanding of its use as a combination therapy in WM and other blood cancers."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.